CNTA CENTESSA PHARMACEUTICALS PLC

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

BOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in TD Cowen’s 44th Annual Health Care Conference in Boston, MA. A fireside chat is scheduled for Tuesday, March 5th at 2:50 PM ET.

The live audio webcast of this event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at .

About Centessa Pharmaceuticals 

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit , which does not form part of this release. 

Contact:

Kristen K. Sheppard, Esq.

SVP of Investor Relations



EN
22/02/2024

Underlying

CNTACENTESSA PHARMACEUTICALS PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTESSA PHARMACEUTICALS PLC

 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offe...

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 mi...

April 24, 2024 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offeri...

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up...

April 23, 2024 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Conce...

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administ...

April 22, 2024 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Reports Business Highlights and Financial Res...

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pha...

March 28, 2024 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Heal...

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference BOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in TD Cowen’s 44th Annual Health Care Conference in Boston, MA. A fireside chat is scheduled for Tuesday, March 5th at 2:50 PM ET. The live audio webcast of this event, as well as an archived recording, will be available under the “Events and Public...

February 22, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch